Loading...
•
Mar 31
Tandem Diabetes Q1 2025 Earnings Report
Tandem Diabetes Care reported its financial results for the quarter ended March 31, 2025, announcing record first quarter sales with worldwide growth of 22%.
Key Takeaways
Tandem Diabetes Care achieved record first quarter sales in Q1 2025, driven by strong worldwide growth and significant increases in pump shipments both domestically and internationally. The company also improved its adjusted EBITDA margin.
Achieved record first quarter sales with worldwide growth of 22%.
Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP basis.
Delivered a 5 point adjusted EBITDA margin increase.
Worldwide sales increased to $234.4 million from $191.7 million in the prior year period.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
For the full year ending December 31, 2025, Tandem Diabetes Care is reaffirming its GAAP financial guidance, projecting sales between $997 million and $1.007 billion and an adjusted EBITDA margin of approximately 3%.
Positive Outlook
- Reaffirming full year GAAP financial guidance.
- Estimated total sales for the full year are approximately $997 million to $1.007 billion.
- Estimated sales in the United States are approximately $725 million to $730 million.
- Estimated sales outside the United States are approximately $272 million to $277 million.
- Estimated gross margin is approximately 54% of sales for the full year.
Challenges Ahead
- Sales outside the United States reflect a $15 million to $20 million headwind associated with preparation for direct commercial operations in select countries.
Revenue & Expenses
Visualization of income flow from segment revenue to net income